|Apr. 27, 2015||Haemonetics Expands Executive Management Roles To Complement Global Growth Strategy|
|BRAINTREE, Mass., April 27, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today expanded roles for two executives. These changes are part of an ongoing plan to advance the Company's global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded ro... |
|Apr. 27, 2015||Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance|
|BRAINTREE, Mass., April 27, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share. Adjusted net income, exclusive of transformation, restructuring and deal amortization expenses detailed below, was $24.5 million, up 1%, and adjusted earnings per share were $0... |
|Mar. 30, 2015||Haemonetics Sets Date for Fourth Quarter and Full Fiscal Year 2015 Earnings Release: April 27, 2015|
|BRAINTREE, Mass., March 30, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) will announce its earnings for the fourth quarter and full fiscal year 2015 and will provide guidance for fiscal year 2016 on April 27, 2015 in a pre-market press release. The Company will hold a webcast to discuss and answer questions about the press release at 8:00 am (EDT) on April 27, 2015.
Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=5188004
|Mar. 24, 2015||Haemonetics Sets Date for Investor/Analyst Meeting - May 19, 2015|
|BRAINTREE, Mass., March 24, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that it will host its annual investor and analyst meeting on Tuesday, May 19th from 9:00 am to 2:30 pm at The State Room, 60 State Street in Boston, Massachusetts.
The agenda for the meeting includes updates on the following:
Current Growth Drivers: Plasma/TEG®/Emerging Markets
Future Growth Drivers: BloodTrack® HaemoBank™/Integrated Software Solutions/Device Connectivity
R&D Up... |
|Mar. 05, 2015||Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement|
|BRAINTREE, Mass. and BOCA RATON, Fla., March 5, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) and CSL Plasma, Inc. announced today that CSL Plasma, Inc. has selected Haemonetics' Next Generation Donor Management System ("NextGen DMS"), an innovative software application for the management of plasma collection, as its future system for managing more than 100 plasma donation centers across the U.S. and Europe. The two companies completed a significant long-term technology agr... |
|Feb. 25, 2015||Haemonetics to Present at the Raymond James 36th Annual Institutional Investors Conference|
|BRAINTREE, Mass., Feb. 25, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Brian Concannon, President & CEO, will present at the Raymond James 36th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2015 at 2:50 pm Eastern time.
The public may access Mr. Concannon's presentation live via webcast at http://wsw.com/webcast/rj95/hae
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood man... |
|Jan. 29, 2015||Haemonetics Reports 3rd Quarter Fiscal 2015 Revenue of $232 Million and Adjusted EPS of $0.53; Reaffirms Revenue and EPS Guidance|
|BRAINTREE, Mass., Jan. 29, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported third quarter fiscal 2015 revenue of $231.8 million, down 4.3%. In constant currency, revenue declined 1.4% in the quarter. The Company reported third quarter GAAP net income of $16.0 million and GAAP net income per share of $0.31. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $27.5 million and adjusted earnings per share were $... |
|Jan. 26, 2015||Due To Winter Storm, Haemonetics Moves Announcement of Third Quarter Fiscal 2015 Earnings Results To Thursday, January 29|
|BRAINTREE, Mass., Jan. 26, 2015 /PRNewswire/ -- Considering the impact of the severe winter storm expected this week on the East Coast, Haemonetics Corporation (NYSE: HAE) will delay by one day the release of its third quarter fiscal 2015 earnings results until 8:00am Thursday, January 29. The press release will also be available on the Company's website at www.haemonetics.com.
Haemonetics will host a webcast to discuss the third quarter and first nine months of fiscal 2015... |